Ireland - English - HPRA (Health Products Regulatory Authority)

bieffe medital spa - sodium chloride - solution for irrigation - 0.9 %w/v

Israel - English - Ministry of Health

baxter healthcare distribution ltd., israel - calcium chloride dihydrate; lactic acid; magnesium chloride hexahydrate; sodium carbonate hydrogen; sodium chloride - solution for haemofiltration - calcium chloride dihydrate 5.145 g / 1000 ml; magnesium chloride hexahydrate 2.033 g / 1000 ml; lactic acid 5.400 g / 1000 ml; sodium chloride 6.45 g / 1000 ml; sodium carbonate hydrogen 3.090 g / 1000 ml - combinations of electrolytes - combinations of electrolytes - as substitution solution in continuous haemofiltration and haemodiafiltration and as dialysis solution in continuous haemodialysis for acute renal failure.

Singapore - English - HSA (Health Sciences Authority)

baxter healthcare (asia) pte ltd - sodium chloride - solution, sterile - 0.9g/100ml - sodium chloride 0.9g/100ml

Singapore - English - HSA (Health Sciences Authority)

vantive pte. ltd. - calcium chloride dihydrate; magnesium chloride hexahydrate; sodium chloride; sodium hydrogen carbonate; sodium lactate - solution - 0.257g/l - calcium chloride dihydrate 0.257g/l; magnesium chloride hexahydrate 0.103 g/l; sodium chloride 6.14g/l; sodium hydrogen carbonate 2.69g/l; sodium lactate 0.336 g/l

Australia - English - Department of Health (Therapeutic Goods Administration)

vantive pty ltd - 45815 - dialysis system anticoagulation solution - solution intended for regional citrate anticoagulation in the extracorporeal circuit during continuous renal replacement therapies.

Australia - English - Department of Health (Therapeutic Goods Administration)

vantive pty ltd - 61616 - haemodialysis dialysate solution - a solution used as a dialysis solution in continuous haemodialysis or continuous haemodiafiltration.

Australia - English - Department of Health (Therapeutic Goods Administration)

vantive pty ltd - 35849 - dialysate, haemodialysis - concentrated solution intended to be used for on-line preparation of haemodialysis, haemodiafiltration and haemofiltration fluids on compatible dialysis systems.

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - cyproterone acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: maize starch; magnesium stearate; povidone; colloidal anhydrous silica; lactose monohydrate; pregelatinised maize starch - women: moderately severe to severe signs of androgenisation. moderately severe/severe forms of hirsutism. moderately severe/severe androgen-dependent loss of scalp hair (moderately severe/severe andogenetic alopecia). moderately severe/severe forms of acne and/or seborrhoea associated with other features of androgenisation. cyproterone acetate inhibits the influence of male sex hormones, which are also produced by the female. it is thus possible to treat diseases in women caused either by increases production of androgens or a particular sensitivity to these hormones. hirsutism and alopecia may be expected to recur over a period of time after cessation of treatment. if meditab cyproterone is taken during pregnancy, the properties of the preparation may lead to signs of feminisation in the male foetus. therefore, in women of child bearing potential, pregnancy must be excluded at the commencement of treatment and ethinyl oestradiol taken as well to ensure contraception. this also promotes regular menstruation. . men: reduction of drive in sexual deviations. meditab cyproterone reduces the force of the sexual urge in men with sexual deviations. whilst under treatment, the man can control himself better in a predisposing stimulatory situation, but there is no influence on any deviating direction of sexual drive. abnormal patterns of sexual behaviour require treatment when they are distressing to the patient. a prerequisite for therapy is the desire by the patient for treatment. meditab cyproterone therapy should be supplemented by psychotherapeutic and sociotherapeutic measures in order to exploit the period of reduced drive for personal and social re-orientation. inoperable prostatic carcinoma. to suppress "flare" with initial lhrh analogue therapy. in long term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred. in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy..

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

baxter healthcare (malaysia) sdn. bhd. - calcium chloride dihydrate; lactic acid; magnesium chloride (hexahydrate); sodium chloride.; sodium hydrogen carbonate. -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

baxter healthcare (malaysia) sdn. bhd. - sodium chloride; sodium citrate -